SecBot SecBot
Insider Buy ·Filed Jul 28, 2026

ARTV

Artiva Biotherapeutics, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed3mo ago SEC0001231919-26-000808
Insider cluster: 1 insiders, $3.1M total
Actionable Insight ▲ Bullish

RA Capital's sustained accumulation at $8.95–$9.99 suggests a strong conviction in ARTV's near-term value. Traders should watch for upcoming clinical data readouts or partnership announcements that could catalyze the stock. The prior cluster of $1.0M in buys on July 23–24 amplifies this signal, consider building a position with a stop below the $8.95 cluster low.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$10.02
T+0 close · Jul 28, 2026 · via day close
Latest settled
−38.12%
T+60 · $6.20
Vs SPY
−43.11%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 29 $10.02entry
  2. T+1 · 4mo ago +4.09%α +2.42% · $10.43
  3. T+5 · 3mo ago +15.67%α +10.14% · $11.59
  4. T+20 · 3mo ago +17.47%α +12.44% · $11.77
  5. T+60 · 26d ago −38.12%α −43.11% · $6.20
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

RA Capital Management, a 10% owner and director, made a series of open-market purchases totaling ~$3.07M over 7 days (July 17–24), with the bulk at $9.55–$9.99 per share. This is a conviction buy from a sophisticated healthcare investor, representing ~1.2% of ARTV's $255M market cap, and follows a prior cluster of $1.0M in RA Capital buys on July 23–24.

Key Financial Metrics

Direction
buying
Total Value
$3.1M
Insiders
1

Key Facts

  • RA Capital Management (Director, 10% Owner) purchased ~313.8K shares total across 5 trades from July 17–24, 2026
  • Total purchase value: ~$3.07M, representing ~1.2% of ARTV's $255M market cap
  • Weighted average purchase price: ~$9.78 per share
  • Prior 30-day insider activity: 9 buys totaling $4.7M, indicating sustained insider accumulation

Financial Impact

RA Capital spent ~$3.07M to acquire ~313.8K shares, ~1.2% of market cap

insider ownershipdilution

Risk Factors

  • Biotech clinical-stage risk, no approved products; pipeline setbacks could erase value
  • Insider buying does not guarantee near-term catalysts; stock may drift without news
  • RA Capital is a large holder, future sales could pressure shares if thesis changes

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
INSIDER-BUY Data (Synthetic)0001231919-26-000808

Track record

33 reports on ARTV

Performance horizon

10 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 16 of 18 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
  2. Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
  3. Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
  4. Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
  5. Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
  6. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  7. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  8. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  10. Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
Showing 10 of 33

US Market Status

Market Closed · Opens in 5h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 29, 2026